Synergistic modulation of cardiac lipid metabolism by Hedan Pill and Shexiang Baoxin Pill through the peroxisome proliferator‐activated receptor α–carnitine palmitoyltransferase 1A axis in experimental heart failure
Abstract Congestive heart failure (CHF) is associated with profound cardiac metabolic remodelling, particularly in lipid utilization. While Hedan Pill and Shexiang Baoxin Pill are traditional Chinese medicines with cardiovascular benefits, their synergistic mechanisms in CHF remain unclear. Network pharmacology and molecular docking were combined with in vivo validation using ApoE −/− mice fed a high‐fat diet and subjected to isoproterenol (ISO) treatment. Animals were allocated to seven groups: control, model, Entresto, Hedan Pill, Shexiang Baoxin Pill, Entresto + Hedan Pill, and Entresto + Shexiang Baoxin Pill. Cardiac function, serum lipids, myocardial histopathology, and protein expression of peroxisome proliferator‐activated receptor α (PPARα), carnitine palmitoyltransferase 1A (CPT1A) and sterol regulatory element‐binding protein 1c (SREBP‐1c) were assessed. Network analysis indicated convergence on the PPARα–lipid metabolism pathway, with strong binding affinities between several active compounds and PPARα (≤ −7.0 kcal mol −1 ). In vivo, Hedan Pill or ShexiangBaoxin Pill alone improved ejection fraction, reduced triglycerides, and alleviated fibrosis and lipid deposition. Compared with Entresto alone, both combination regimens further reduced serum triglycerides and LDL‐C, whereas ejection fraction did not differ significantly. Mechanistically, both agents upregulated myocardial PPARα and CPT1A while suppressing SREBP‐1c. Hedan Pill and Shexiang Baoxin Pill synergistically improve cardiac lipid metabolic homeostasis through the PPARα–CPT1A axis, thereby protecting against CHF‐induced myocardial injury. These findings provide physiological and mechanistic evidence supporting their translational potential as complementary interventions in CHF.
Authors
- Linjun Xie (ORCID: https://orcid.org/0009-0005-3561-2693)
- Cheng Cao (ORCID: https://orcid.org/0000-0002-8923-1758)
- Feng Wang (ORCID: https://orcid.org/0000-0001-7203-0098)
- Lixin Wang (ORCID: https://orcid.org/0000-0002-5016-4690)
- Xinyuan Ding (ORCID: https://orcid.org/0000-0002-8982-6807)
- Zhang Qian
- Xinxin Yan
- Ping Li
- Yu Wang
- Guanghao Niu
- Yanxia Yu
- Yuan Li (ORCID: https://orcid.org/0009-0008-0173-8943)
Institutions
- Soochow University (CN)
- Suzhou Municipal Hospital (CN)
- The Fifth People’s Hospital of Suzhou (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Experimental Physiology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1113/ep093334
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00